Investigation of the Cylex® ImmuKnow® Assay
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Aplastic Anemia, Chronic Myelogenous Leukemia
Both
Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Aplastic Anemia, Chronic Myelogenous Leukemia
Trial Information
Investigation of the Cylex® ImmuKnow® Assay
Inclusion Criteria:
Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for
any of the following disorders are eligible:
1. Acute leukemia
2. Non-Hodgkin's Lymphoma
3. Chronic lymphocytic leukemia
4. Hodgkin's disease
5. Multiple myeloma
6. Myelodysplastic Syndromes
7. Myeloproliferative Disorders
8. Aplastic Anemia
9. Chronic myelogenous leukemia
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Principal Investigator
Sherif Farag, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Indiana University Simon Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
0710-11/ IUCRO-0207
NCT ID:
NCT00569842
Start Date:
November 2007
Completion Date:
December 2012
Related Keywords:
- Leukemia
- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia
- Hodgkin's Disease
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Aplastic Anemia
- Chronic Myelogenous Leukemia
- Anemia
- Anemia, Aplastic
- Hodgkin Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Lymphoma
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Myelodysplastic Syndromes
- Preleukemia
- Myeloproliferative Disorders
Name | Location |
|---|---|
| Indiana Universtiy Simon Cancer Center | Indianapolis, Indiana 46202 |
